The FDA-approved imaging agent for detecting coronary artery disease gained Medicare and Medicaid coverage starting April 1.

GE HealthCare is also using ACC 2025 to highlight new AI-powered innovations for cardiac care: The latest version of CASE (Cardiac Assessment System for Stress Testing), powered by the company’s ...

GE HealthCare has delivered the initial subject doses of a positron emission tomography (PET) myocardial perfusion imaging (MPI) agent, Flyrcado (flurpiridaz F 18) injection, to detect coronary ...

Flyrcado brings the first practical opportunity to combine exercise stress testing with cardiac PET imaging for CAD, enabling the most robust protocol for evaluating ischemia in patients.

It will provide facilities for dose calculation, enhanced quality of images, care coordination ... will be supported by GE HealthCare's new Omni Legend 32cm PET/CT, SIGNA PET/MR and several ...